A method for preparing 2-alkylanthracene includes the step of separating 2-alkylanthracene from a reaction product of anthracene alkylation reaction. The anthracene alkylation reaction is a reaction of anthracene and an alkylation reagent under an alkylation condition and in the presence of an alkylation reaction solvent and a catalyst. The reaction product of the anthracene alkylation reaction contains anthracene and the product of a series of alkylanthracenes containing 2-alkylanthracene.

The present application discloses methods for the efficient preparation of high purity compounds of the Formula I, and their methods of use. ##STR00001##

The present application discloses methods for the efficient preparation of high purity compounds of the Formula I, and their methods of use. ##STR00001##

The present application discloses methods for the efficient preparation of high purity compounds of the Formula I, and their methods of use. ##STR00001##

Disclosed is a continuous solid/liquid extraction device including at least, from upstream to downstream: a mixer including an inlet and an outlet; an extraction coil including an inlet and an outlet, the inlet of the coil being connected to the outlet of the mixer; and a phase separator connected to the outlet of the coil. The same coil includes an ultrasonic probe with radial irradiation placed in the center of the coil.

Disclosed is a continuous solid/liquid extraction device including at least, from upstream to downstream: a mixer including an inlet and an outlet; an extraction coil including an inlet and an outlet, the inlet of the coil being connected to the outlet of the mixer; and a phase separator connected to the outlet of the coil. The same coil includes an ultrasonic probe with radial irradiation placed in the center of the coil.

Provided is a production method capable of efficiently producing a reduced coenzyme Q10 Form II crystal. A method for producing reduced coenzyme Q10 crystals comprises warming a mixture of a reduced coenzyme Q10 Form I crystal and a reduced coenzyme Q10 Form II crystal to 32° C. or higher, in the presence of 0.001 to 50 parts by weight of a solvent with respect to 100 parts by total weight of the crystals, so as to increase the content of the reduced coenzyme Q10 Form II crystal. The warming time may be 1 hour or more and less than 14 hours, and after the warming of the mixture in the presence of the solvent, drying may be performed at 45° C. or higher to remove the solvent.

Provided is a production method capable of efficiently producing a reduced coenzyme Q10 Form II crystal. A method for producing reduced coenzyme Q10 crystals comprises warming a mixture of a reduced coenzyme Q10 Form I crystal and a reduced coenzyme Q10 Form II crystal to 32° C. or higher, in the presence of 0.001 to 50 parts by weight of a solvent with respect to 100 parts by total weight of the crystals, so as to increase the content of the reduced coenzyme Q10 Form II crystal. The warming time may be 1 hour or more and less than 14 hours, and after the warming of the mixture in the presence of the solvent, drying may be performed at 45° C. or higher to remove the solvent.

Disclosed herein are methods of treating or suppressing a disorder selected from the group consisting of α-synucleinopathies, tauopathies, ALS, traumatic brain injury, and ischemic-reperfusion related injuries.ury, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the formula: or the hydroquinone form thereof; or a solvate or hydrate thereof.

Disclosed herein are methods of treating or suppressing a disorder selected from the group consisting of α-synucleinopathies, tauopathies, ALS, traumatic brain injury, and ischemic-reperfusion related injuries.ury, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the formula: or the hydroquinone form thereof; or a solvate or hydrate thereof.